Navigation Links
In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop
Date:10/7/2008

CAMBRIDGE, Mass., Oct. 7 /PRNewswire/ -- Taligen Therapeutics Inc. today announced that in vivo data on several of the Company's pipeline candidates were presented at the XXII International Complement Workshop in Basel, Switzerland. The data highlighted the candidates' efficacy in several animal models of complement-mediated diseases.

"These highlighted presentations, as well as several in vitro studies presented at the conference, reveal the deep expertise and expanding knowledge base within the complement research community," said Michael Holers, M.D., chief scientific officer of Taligen Therapeutics. "The work, not only from our laboratory but from the laboratories of our collaborators, is unlocking the mechanisms of immunomodulation and enabling Taligen to direct the development of new product candidates and test them in a variety of animal models as a precursor to their clinical development."

"The opportunity to further evaluate Taligen's TT30 compound in our research activities has been invaluable in our characterization of the effects of modulation of the complement system on animal models of human disease," said Steve Tomlinson, Ph.D. and principal investigator of several studies presented at the complement meeting. "Our results in the MRL lupus model in collaboration with Dr. Gary Gilkeson's group now show that targeted complement inhibition using TT30 leads to both local control of inflammation as well as a substantial decrease in the autoimmune response in vivo. No other type of compound has this dual profile of activity. I also believe these CR2-targeted compounds will help future research in the lupus area and hopefully provide therapeutic options for patients."

Key findings from several of the studies testing Taligen's product candidates are highlighted below:

Data support targeting the alternative complement pathway using TT30 as an immunomodulatory compound for treating complement-mediated diseases

In vivo st
'/>"/>

SOURCE Taligen Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
2. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
3. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
4. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
5. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
6. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
7. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
8. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
9. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
10. Tobira Therapeutics Inc. Receives US Patent for TBR-652
11. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014  In recognition of the increased ... from the flu, pneumonia, shingles and other illnesses, ... declared September to be Senior Vaccination Month. Because ... is important that adults ages 65 years and ... CVS pharmacists and MinuteClinic nurse practitioners and physician ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... Therapeutics in Asia-Pacific Markets to 2020 ... Unmet Need in Newly Diagnosed and ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html Glioblastoma ...
(Date:8/28/2014)... , Aug. 28, 2014 Telik, Inc. ... company that merged with MabVax Therapeutics, Inc. on ... significant progress related to the development of its ... was recovered using the Company,s internally developed antibody ... potential for multiple antibody based therapeutic and diagnostic ...
Breaking Medicine Technology:September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4
(Date:8/28/2014)... 2014 Kirklyn Smith, an office manager for ... a new world’s record by walking 5,000 miles in a ... constantly amazed by the thousands of individual stories of TrekDesk ... to stand out more than the others. , Kirklyn has ... count which tallies a range of 54,823 steps (presumably on ...
(Date:8/28/2014)... (HealthDay News) -- Lack of sleep not only puts teens ... increased risk for obesity, researchers warn. The study authors ... were aged 16 and 21. Nearly one-fifth of them got ... were age 16, and this group was 20 percent more ... got more than eight hours of sleep per night at ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 NJ ... Institute of North Jersey. , NJ Top Doc, ... is now a certified medical examiner for the ... certified by the department to perform all drug ... training in diagnosing and treating musculoskeletal disorders including ...
(Date:8/28/2014)... In 2012, The Ben & Catherine Ivy Foundation ... brain cancer research projects at the Translational Genomics ... officially received the final regulatory approval from University ... for the trial can begin. , In the ... Trial," TGen and its clinical partners will lead ...
(Date:8/28/2014)... August 28, 2014 As Mirena IUD ... around the U.S., Bernstein Liebhard LLP notes that a ... like Mirena as ideal birth control for teenage girls. ... authors of the study point out that IUDs are ... other methods favored by this patient population. Their study, ...
Breaking Medicine News(10 mins):Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:Less Sleep in Teen Years Tied to More Pounds at 21 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 3Health News:TGen receives approval for patient enrollment in brain cancer clinical trial 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 3Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 4
... HOUSTON, Feb. 2, 2009 Stuart Dryer, the John and ... chair at the University of Houston, has been awarded the ... of Science (AAAS). AAAS is the world,s ... have made distinguished contributions to the advancement of science. ...
... Feb. 2, 2010 News media and others interested ... next in a series of American Chemical Society (ACS) ... variety of pertinent career topics impacting science and engineering ... p.m. Eastern Time, the free webinar will feature Carolyn ...
... that tension on DNA molecules can affect gene expression---the process ... what to do. Scientists understand the chemistry involved ... The U-M group is believed to be the first to ... Their paper is published in the current edition of ...
... Government ... in which he will oversee all of the publisher’s editorial and commercial operations. , ... Washington, DC (PRWEB) Feb. 4, 2010 ... General Manager, a role in which he will oversee all of the publisher’s editorial and ...
... ... to Stay Awake and Alert , ... Jackson, CA (PRWEB) February 2, 2010 -- 5150 Juice (5150juice.com) today announced a handy ... up to 500mgs per ounce of caffeine to turn any drink into a Super Energy ...
... Former ... StatCom in a strategic partnership program that helps hospitals transform throughput operations. , ... Atlanta, GA (PRWEB) February ... MBA, to the StatCom transformation team as enterprise vice president, Western region. Previously, Thalken ...
Cached Medicine News:Health News:Biology professor becomes 5th at UH to reach prestigious AAAS status 2Health News:ACS webinar features tips for finding and building a career in the food and flavor industries 2Health News:Mechanical forces could affect gene expression 2Health News:Government Executive Media Group Completes Leadership Search 2Health News:Government Executive Media Group Completes Leadership Search 3Health News:5150 Juice Launches Pocket-Sized Syringe Containing 166.6mg of Liquid Caffeine for Consumers to Add To Their Favorite Drink 2Health News:5150 Juice Launches Pocket-Sized Syringe Containing 166.6mg of Liquid Caffeine for Consumers to Add To Their Favorite Drink 3Health News:Mary Kay Thalken Joins StatCom as Enterprise VP, Western Region 2Health News:Mary Kay Thalken Joins StatCom as Enterprise VP, Western Region 3
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The Pe-Plus offers an additional clinical option for replacing the acetabulum....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Medicine Products: